Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833635 | 0.86 | TRPA1 (0.55) | SIGMAR1TRPA1TRPV1CYP1A2EPHX1 | |
| Ammonia Solution, Strong SCHEMBL29021310 | 0.84 | TRPA1 (0.53) | SIGMAR1TRPA1TRPV1CYP1A2EPHX1 | |
| SCHEMBL2187692 | 0.82 | SIGMAR1 (0.49) | SIGMAR1TRPA1 | |
| SCHEMBL13335507 | 0.82 | SIGMAR1 (0.49) | SIGMAR1TRPA1 | |
| SCHEMBL2185725 | 0.82 | SIGMAR1 (0.49) | SIGMAR1TRPA1 | |
| SCHEMBL3398678 | 0.81 | IGF1R (0.57) | SLC18A3SIGMAR1MMEMEN1NPC1 | |
| SCHEMBL2457986 | 0.80 | CYP3A4 (0.46) | SLC18A3SIGMAR1MME | |
| SCHEMBL29158041 | 0.80 | CYP3A4 (0.46) | SLC18A3SIGMAR1MME | |
| SCHEMBL5785218 | 0.80 | MAPT (0.55) | SLC18A3MMEMEN1NPC1RAB9A | |
| Benzyl Alcohol SCHEMBL11361278 | 0.79 | TSHR (0.70) | MMETRPA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129381-B2 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20050059614-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059614-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A2, SLC5A1, SLC2A2 | SLC18A3 1376/4885SIGMAR1 1692/4885MME 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.